|
C1ORF109 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62714286489063E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.88178419700125E-15 |
| Normal-vs-Stage2 |
1.004140E-04 |
| Normal-vs-Stage3 |
1.63900004679363E-11 |
| Normal-vs-Stage4 |
2.48799980617775E-10 |
| Stage1-vs-Stage2 |
1.546840E-01 |
| Stage1-vs-Stage3 |
4.691600E-01 |
| Stage1-vs-Stage4 |
3.415600E-01 |
| Stage2-vs-Stage3 |
7.189900E-02 |
| Stage2-vs-Stage4 |
6.355900E-02 |
| Stage3-vs-Stage4 |
7.454600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
5.77889999999748E-05 |
| Normal-vs-Asian |
3.47499999997503E-06 |
| Caucasian-vs-AfricanAmerican |
4.347400E-01 |
| Caucasian-vs-Asian |
7.520000E-02 |
| AfricanAmerican-vs-Asian |
6.550600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.21098703182088E-12 |
| Normal-vs-Female |
1.65600866353088E-12 |
| Male-vs-Female |
7.851200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.67044156285101E-12 |
| Normal-vs-Age(41-60Yrs) |
7.06970038066856E-11 |
| Normal-vs-Age(61-80Yrs) |
7.79060149724842E-11 |
| Normal-vs-Age(81-100Yrs) |
1.756010E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.735000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.901000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.856600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.665000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.850400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.511000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.339600E-02 |
| Classical-VS-Follicular |
9.126000E-02 |
| Classical-VS-Other |
6.795600E-01 |
| Classical-VS-Normal |
1.65945035490722E-12 |
| Tall-VS-Follicular |
1.235850E-02 |
| Tall-VS-Other |
5.964000E-01 |
| Tall-VS-Normal |
2.52200005323999E-09 |
| Follicular-VS-Other |
4.051600E-01 |
| Follicular-VS-Normal |
1.2665999999939E-06 |
| Other-VS-Normal |
4.283900E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.01859981455266E-10 |
| Normal-vs-N1 |
2.60980126398636E-12 |
| N0-vs-N1 |
1.315600E-02 |
|
|
